Abstract
Objective: Despite platinum-based chemoradiation (C-XRT), 40%–50% of women with locally advanced cervical cancer will die from their disease. Nelfinavir (NFV), a protease inhibitor, has been shown to target the Akt pathway sensitizing cancer cells to chemoradiation. The objective of this phase I trial was to evaluate the safety and tolerability and identify the recommended phase II dose (RP2D) of NFV in combination with standard concurrent C-XRT in locally advanced cervical cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
